ONC206

Phase 2Small molecule

Jazz Pharmaceuticals

ONC206 is one of 117 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

ParagangliomaActive, not recruiting

Central Nervous System NeoplasmActive, not recruiting

GliomaPhase 1

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Central Nervous System NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

2 2

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 3

Vepesid

AAvyxa

Phase 3

4 4

Photofrin

PPinnacle Biologics Inc.

Phase 3

2 5

Ifex

BBaxter Healthcare Corporation

Phase 3

1 6

Velban

EEastern Cooperative Oncology Group

Phase 3

1 7

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 8

Rayos

RRoxane Laboratories

Phase 3

1 9

Modeyso

CChimerix

Phase 3

3 10

IFN-α

PPeking University People's Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Central Nervous System Neoplasm

NCT04541082

Q3 2027

Phase 1Recruiting

Glioma

NCT04732065

Q4 2028

Phase 2Recruiting

Paraganglioma

NCT07282587

Clinical

Trials by Indication[1]

Central Nervous System Neoplasm1 trial

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 1·NCT04541082·102 enrolled

Paraganglioma1 trial

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT07282587·90 enrolled

Glioma1 trial

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Recruiting·SSabine Mueller, MD, PhD·Phase 1·NCT04732065·208 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ONC206. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ONC206 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ONC206. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Jazz Pharmaceuticals

ONC206

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2028

Trials by Indication[1]

Central Nervous System Neoplasm1 trial

Paraganglioma1 trial

Glioma1 trial

References

Drug Info

Quick Facts

Related News